Tras las primeras advertencias sobre el brote de VIH en Grecia, el OEDT encargó un análisis rápido de la situación con respecto a los últimos datos epidemiológicos y las medidas de prevención adoptadas.

Más información, en inglés, está disponible abajo.

Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas.


This report notes that in 2011, the number of newly reported cases of HIV infection among injecting drug users in Greece has sharply increased. By the end of July, 113 cases had been reported in the Hellenic Centre for Disease Control and Prevention’s surveillance system while, from 2001 to 2010, the number of reported cases ranged from 3 to 19 a year. There were no changes reported in testing policy that could explain this increase. The overwhelming majority of new cases have been detected in Athens.

Preliminary data suggest that 62% of the reported injecting drug users were of Greek origin, 15% were immigrants and 23% were of unknown ethnicity.

Prevalence of antibodies to HIV among injecting drug users ranged from 0.3–0.8% during the years 2002–2010. In the first seven months of 2011, a sharp increase was observed in all data sources.

In 2011, molecular analysis revealed that 22 out of 23 positive samples (96%) were found to belong to injecting drug user networks. Analysis suggested that the origin of the virus was from Asia (12 cases), Greece (7 cases) and from South-western Europe (Portugal and Spain) (3 cases).

A number of hypotheses exist in regard to the possible contributory factors for the increased number of new HIV cases: they include increased levels of sexual and drug-related risk behaviour, and the absence of comprehensive HIV-prevention programmes. It has also been suggested that other factors, including targeting of drug injectors by the police may have inhibited service uptake or encouraged more risky forms of use.

Considering the estimated number of problem drug users, Greece has relatively few low-threshold programmes for drug injectors. The opioid substitution programme — a measure with high efficacy in preventing HIV transmission among injecting drug users — has a waiting list of five to seven years. At the end of June 2011, 5 573 drug users were reported to be actively enrolled in opioid substitution programmes in Greece. However, it was also reported that 7 428 (3 500 in Athens) additional applications for treatment were pending, resulting in relatively low coverage of opioid substitution treatment (see Figure HSR-1 in the 2011 Statistical bulletin). All HIV-positive injecting drug users, including illegal immigrants, are offered priority access to opioid substitution treatment and anti-retroviral therapy.

Anonymous HIV/AIDS screening and counselling, as well as anti-retroviral therapy for HIV-positive people and their sexual partners, are provided for by law and are widely available.

Syringe and injecting equipment exchange or distribution programmes are available, but their coverage is very limited (see Figure HSR-3 in the 2011 Statistical bulletin).

A number of steps are being taken to address the HIV outbreak, with a focus on improving the availability of prevention and health interventions for drug injectors. These include:

  • Intensification of programmes providing needles, syringes and condoms in downtown Athens (January 2011);
  • A switch in the kind of syringes being offered (from high to low dead space syringes) is under way (September 2011);
  • Systematic HIV screening of injecting drug users in treatment programmes has been initiated (September 2011);
  • An awareness campaign directed at injecting drug users was implemented in the centre of Athens (March 2011);
  • A molecular epidemiology surveillance programme was initiated to describe the transmission networks, determine the origin of HIV strains and to identify index cases (May 2011);
  • A major restructuring of opioid substitution programmes is also underway, and is expected to eliminate the waiting list by the end of 2011.